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Abstract
BACKGROUND: In this study, we report on the use of a
new, bolus-injectable, carboxymethyl dextran–based
magnetic nanoparticle (MNP), ferumoxytol, to improve
detection in loco-regional lymph nodes by magnetic
resonance imaging (MRI). METHODS: This preliminary
study was performed as a prospective, single-center,
open label pilot study to determine the magnitude of
nodal MRI signal changes and to determine the opti-
mal time points for imaging following intravenous (IV)
bolus injection of the MNP. The study group consisted
of 10 patients, all of whom were diagnosed with pros-
tate cancer before any systemic therapy. RESULTS:
All 10 patients had lymph nodes evaluated by histopa-
thology. Of the evaluated 26 lymph nodes, 20 were
benign and 6 were malignant. The mean short-axis
diameter of benign lymph nodes was 6 mm and the
mean short-axis diameter of malignant lymph nodes
was 7 mm. Following IV administration, there was a sig-
nificant change in mean signal-to-noise ratio (SNR) of
benign lymph nodes (P < .0001) whereas there was little
change in the mean SNR of malignant nodes (P = .1624).
No adverse events were encountered. CONCLUSION:
Ferumoxytol is safe and, at the appropriate circulation
interval, modulates nodal signal intensity, allowing for
identification of malignant nodal involvement by MRI.
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Introduction
Nanotechnology has been hailed as an enabling science,
leading to new drugs, products, sensors, and devices, and
has been most successful in the preclinical area [1]. Despite
numerous advances, including a National Nanotechnology
Initiative [2,3], clinical translation has been slow. In fact, to
date, the most successful clinical nanomaterials have been
diagnostic imaging agents [1]. Based on anecdotal studies
that certain nanomaterials (e.g., tantalum and thorium di-
oxide nanoparticles) have a propensity for accumulating in
nodal macrophages, we designed biocompatible and mag-
netic resonance imaging (MRI)–detectable analogs nearly
two decades ago [4]. These materials (originally dubbed
ultrasmall superparamagnetic iron oxide [USPIO] and later
monocrystalline iron oxide nanocolloid [MION]) were dextran
T10–coated superparamagnetic nanoparticles in the 20- to
50-nm size range, with variable coating thickness to impart dis-
tinct pharmacokinetic properties and macrophage recognition
through opsonization and/or protein binding. We subsequently
conducted clinical trials on one prototype, ferumoxtran-10
(Combidex; AMAG Pharmaceuticals Inc., Cambridge, MA), as
the first systemically injectable lymphotropic imaging agent [5,6].
In subsequent larger-scale trials, we and others were able to
demonstrate extraordinary efficacy of this material [7–10]. How-
ever, despite this proven efficacy, ferumoxtran-10 has some
logistical disadvantages, including the need for a slow infusion
to minimize hypersensitivity-related side effects.
In an effort to produce nanomaterials with improved surface
coatings, higher iron payloads and ability for bolus injection,
carboxymethyl dextran (polyglucose sorbitol carboxymethyl-
ether) nanoparticles have been developed as next-generation
nanoparticles. One such clinical prototype preparation, feru-
moxytol (Code 7228; AMAGPharmaceuticals Inc.), is being de-
veloped for iron replacement therapy in anemia [11–13]. The
safety profile of ferumoxytol in phase I and II clinical trials has
been very good (better than oral elemental iron), enabling the
administration at substantially higher doses compared to feru-
moxtran10. In the anemia setting, 1000mg Fe of nanoparticles
is administered intravenously (IV) in two settings, roughly four
times the diagnostic dose of the earlier ferumoxtran10 (2.6 mg
Fe/kg). Ferumoxytol also has a shorter blood half-life in hu-
mans (10–14 hours) and greater T1 shortening of blood (in-
creased signal of blood vessels) leading to its past exploration
as a vascular imaging agent for MRI [12]. It has remained
unclear, however, whether the therapeutic agent ferumoxytol
can be used as a diagnostic lymphotropic imaging agent given
its different effects on tissue relaxation times. In particular, the
dose and the time to image after magnetic nanoparticle (MNP)
administration to achieve maximal contrast within human lymph
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nodes remain unknown. The purpose of this exploratory study
was to test this bolus-injectable MNP in patients with prostate
cancer with possible nodal spread, to document changes in
nodal signal intensities as a function of time (serial imaging),
and to document side effects upon bolus injection.
Materials and Methods
This exploratory study, sponsored by the National Cancer
Institute, was performed as a prospective, single-center,
single-dose, open label pilot study and was approved by
the Institutional Review Board.
Subjects
Subjects with prostate cancer who were scheduled for a
surgical lymph node dissection were eligible for this study.
Other entry criteria included the following: age > 18 years;
no prior therapy for metastatic disease; no evidence of iron
overload; and normal liver function tests. Subjects with a
known iron allergy were also excluded.
Study Procedures
Nanoparticle Ferumoxytol (AMAG Pharmaceuticals Inc.) is
a superparamagnetic iron oxide nanoparticle designed to
minimize immunologic sensitivity. The crystal size of the iron
oxide core is 6.8 ± 0.4 nm in diameter as measured by X-ray
diffraction [12]. The nanoparticle is formulated to be isotonic
at a concentration of 30 mg Fe/ml. The physical, pharmaco-
kinetic, and biologic properties of ferumoxytol in therapeutic
trials have been reported [11,12]. Ferumoxytol was ad-
ministered at a dose of 4 mg of Fe/kg, injected at a rate
of 2 ml/sec by using a power injector (Medrad Spectris;
Medrad, Indianola, PA). A 15-ml normal saline intravenous
flush was given after the nanoparticle administration. Vital
signs were monitored throughout the entire study and 2 hours
after termination of imaging.
Patients The study group consisted of 10 patients (mean
age 53.8 years; range 43–70 years), all of whom were diag-
nosed with prostate cancer before any systemic therapy.
Patient characteristics are summarized in Table 1.
The patients were screened for known allergy or hyper-
sensitivity reactions to parenteral iron, parenteral dextran,
parenteral iron–dextran, or parenteral iron–polysaccharide
preparations and, if present, were excluded from the study.
Similarly, any pre-study documented ferritin level in the
available medical records greater than 800 ng/ml and per-
cent saturation of transferrin level greater than 60% or any
laboratory/clinically confirmed history of iron overload or
hemachromatosis resulted in exclusion from the study.
MR imaging MR imaging of the pelvis was performed on a
1.5-T scanner (Signa; General Electric Medical Systems,
Milwaukee, WI) using a pelvic phased array coil. T1-, T2-,
and T2*-weighted imaging was performed from the pubic
symphysis to the aortic bifurcation in the axial and coronal
plane using the following parameters: 1) T2-weighted fast
spin-echo: repetition time 4500 to 5500 msec, echo time 80
to 100 msec, flip angle 90j, number of excitations 3, slice
thickness 3 mm, gap 0, matrix 256  256, field of view 22 to
30 cm; and 2) T2*-weighted gradient-echo: repetition time
2100 msec, echo time 21 msec, flip angle 20j, number of ex-
citations 2, slice thickness 3 mm, gap 0, matrix 160 256, field
of view 22 to 30 cm. Imaging was performed before, and at
5, 18, and 24 hours following the intravenous administration of
ferumoxytol. Imaging times ranged from 30 to 45 minutes. All
patients were imaged with the same sequence parameters.
Follow-up All patients were followed up for adverse events.
The patient’s vital signs including pulse oximetry, heart
rate, and blood pressure were recorded just before the feru-
moxytol infusion, every 5 minutes for 30 minutes following
the ferumoxytol bolus and every 30 minutes following the
ferumoxytol injection for a minimum of 2 hours. The patients
were monitored for adverse events for 2 hours after the in-
fusion and at every patient visit thereafter. At every subse-
quent MRI time point, the vitals were repeated and patients
were again evaluated for adverse events at each contact time.
The pathologic outcomes from their lymph node dissection
were recorded. Patients were followed up for 2 weeks follow-
ing the termination of the entire study to determine any pos-
sible side effects from ferumoxytol administration.
Image Analysis
Signal-to-noise ratios (SNRs) of muscle, fat, bone mar-
row, and lymph nodes were determined on T2*-weighted im-
ages by placing operator-defined region-of-interest. SNR
was determined by dividing the mean signal intensity of a
lymph node by the standard deviation of background noise.
The paired Student’s t test was used to evaluate the statistical
significance between benign and malignant lymph nodes at
different time points.
Results
All patients completed the study and no adverse events
were noted during nanoparticle injection or within 2 weeks
of follow-up. Of the 10 patients, 4 also had surgical nodal
dissection of lymph nodes [benign (n = 3); malignant (n = 1)]
and 6 had image-guided lymph node biopsy [benign (n = 4);
malignant (n = 2)]. The mean size of the biopsied lymph
nodes was 8 mm (range 7–11 mm). A total of 26 lymph
nodes were then evaluated histopathologically. Of these, 20
were benign and 6 were malignant. The mean short-axis
Table 1. Characteristics of Patients Enrolled in the Study.
Patient Age (years) PSA (ng/ml) Gleason Score Clinical T Stage
1 55 20.3 6 T1c
2 46 4.4 7 T2c
3 44 7.07 6 T1c
4 58 27 9 T2
5 70 16.8 7 T1c
6 51 4.6 9 T1c
7 62 6 9 T2b
8 60 7.4 7 T2a
9 43 0.1 6 T2
10 49 2.6 6 T2a
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diameter of benign lymph nodes was 6 mm and the mean
short-axis diameter of malignant lymph nodes was 7 mm.
Effect of the Nanoparticle on Normal Tissues
Figure 1 summarizes the SNR of different tissues (mus-
cle, fat, bone marrow, and lymph node) for different patients
as a function of IV administration of ferumoxytol. In muscle
and fat, SNR did not change appreciably (P > .5), whereas
that of bone marrow decreased slightly. In contradistinction,
SNR of benign lymph nodes decreased in all patients.
Effect of the Nanoparticle on Malignant Lymph Nodes
Figure 2A compares MR signal intensities in normal and
metastatic lymph nodes on a group by group basis. As ex-
pected, benign and malignant nodes had similar SNR before
administration of nanoparticle (P = .27). Following IV admin-
istration, there was a significant change in mean SNR of be-
nign lymph nodes (9.26 ± 2.11 to 2.94 ± 1.34, representing a
68.2% change; P < .0001). In contradistinction, there was little
change in the SNR of malignant nodes (7.46 ± 1.83 to 6.83 ±
1.35, representing an 8.5% change; P = .1624). Figure 2B
plots the mean nodal signal intensity as a function of time and
Figure 2C summarizes the mean difference between benign
and malignant lymph nodes. As is evident, of all the time
points evaluated, maximum contrast within lymph nodes was
reached 24 hours after administration of nanoparticles and
was 100% higher than during precontrast imaging.
Figure 3 is an example of a normal inguinal lymph node in
a patient with prostate cancer. Serial imaging shows a time-
dependent decrease of nodal signal intensity that reaches a
maximum at 24 hours after administration. Note that the
lymph node appears somewhat heterogeneous at 18 hours.
Figure 4 is an example of a nonenlarged malignant perirectal
lymph node. Unlike in Figure 3, signal intensity changes are
minor, indicative of malignancy.
A recent advance in automated nodal staging has been
the development of automated segmentation, analysis, and
visualization software [14]. To test whether these methods
could be applied to ferumoxytol-based data sets, we chose to
investigate benign and malignant examples. As is shown in
Figure 5, semiautomated algorithms could be used to visu-
alize the spatial location of individual nodes (and their status)
in relations to pelvic vessels, bladder, prostate, and pelvis.
Discussion
Magnetic nanoparticles have become important tools for
clinical cancer imaging [1,7,14]. A number of monocrystalline
[15] and ultrasmall iron oxide [4] preparations have been
developed over the last decade and have been shown to
significantly improve the accuracy of nodal cancer staging
[5,7,14,16]. They have also allowed steady-state angio-
genesis imaging [17] and mapping of tumor host response
(monocyte/macrophage phagocytosis) [18]. More recently,
magnetofluorescent nanoparticles have been used experi-
mentally for preoperative staging and intraoperative tumor
localization [19]. Finally, molecularly targeted MNPs may
enable high-resolution mapping of specific molecular targets
and cellular components [20].
One of the most widely tested magnetic nanomaterials for
in vivo imaging has been dextran-coated monocrystalline
iron oxide. Recently, we confirmed earlier mouse model work
[16] and showed that nanoparticle-enhanced MRI is vastly
superior to other noninvasive methods of identifying lymph
node metastases from solid tumors [7,14]. In addition, MRI
can identify malignant lymph nodes outside the usual field of
Figure 1. Line graph showing SNR changes of normal tissue and lymph nodes before and 24 hours after administration of ferumoxytol (4 mg Fe/kg). Most tissues
and malignant nodes show little or no change in SNR in comparison to benign lymph nodes.
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tumor resection, thus upstaging a proportion of cases that
would have been classified as node-negative by conven-
tional surgical staging. This method is useful for detecting
loco-regional metastases that do not produce an overall in-
crease in lymph node size andmay be particularly valuable in
clinical situations where surgical resection of all nodal tumor
sites has been shown to improve cure rates (i.e., testicular
and bladder cancer).
Figure 2. (A) Scatter plot showing distribution of mean SNR values for benign and malignant node groups at different time points. P values reflect the statistical
significance at different time points. (B) Line graph summarizing the mean change of malignant and benign nodal SNR over time. (C) Plot of CNR ratio between
malignant and benign lymph nodes as a function of time. Note that overall contrast increases f100% and that maximum CNR is reached at 24 hours.
Figure 3. Benign right external iliac node. (A) Axial contrast-enhanced computed tomographic (CT) image shows an enlarged right external iliac node. (B) Sequential
images show progressive loss of signal following ferumoxytol administration. (C) CT-guided biopsy showing biopsy needle within the enlarged lymph node.
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The current preliminary study was designed to test whether
an emerging, next-generation carboxymethyl dextran–based
iron oxide nanoparticle (ferumoxytol) could be used to achieve
similar results in nodal staging. Ferumoxytol was designed to
minimize allergic reactions, such as those seen with commer-
cially available iron dextran products, and to minimize free iron
during dosing. By virtue of its different coating, ferumoxytol
has a lower risk of immunogenicity, a better safety profile,
and can be given by bolus administration [12,13]. However, it
had also been reported to result in much more pronounced
T1 shortening of blood and tissues, whereas its effects on
nodal signal intensity (and hence its use for nodal staging)
Figure 4. Malignant left perirectal node. (A) Axial precontrast gradient-echo image shows a hyperintense left perirectal lymph node (arrow). (B) 24 hours after
ferumoxytol, the node shows no signal change indicating malignant infiltration. (C) CT-guided biopsy of the node. (D) Subsequent pathologic evaluation showed
architectural distortion from malignant infiltration of prostate cancer.
Figure 5. Three-dimensional (3D) rendered images following IV administration of nanoparticles. (A) 3D rendered image from a patient shows multiple benign nodes
(in green) plotted in relation to pelvic vessels and bony pelvis. (B) 3D rendered image of another patient shows malignant node (in red) in relationship to pelvic
vasculature along with other benign nodes. (C) Same node in B is shown in relationship to pelvic vessels, bony pelvic, and the prostate gland.
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remained unknown. Our results indicate that ferumoxytol in-
deed alters nodal signal intensity on T2*-weighted MRI in a
time-dependent fashion. Specifically, we show that the differ-
ence between normal and malignant nodes is highest 24 hours
after administration. This preparation has the potential to be-
come the next-generation lymphotrophic MR imaging agent.
We used a dose of 4 mg of Fe/kg, higher than the dose
previously used in ferumoxtran clinical trials (2.6 mg Fe/kg).
Despite the higher dose, the signal changes were less pro-
nounced than those with ferumoxtran and the differentiation
(delta contrast-to-noise [CNR]) was lower than with a lower
dose of ferumoxtran. To increase the differential and further
improve differentiation of benign and malignant nodes, we
expect that higher doses will be ultimately required. Because
higher doses of ferumoxytol can be given therapeutically
(typically 1000 mg vs 280 mg as was the case for this diag-
nostic study) with few side effects, this distinct possibility
exists and should be studied. It should also be noted that, as
expected from the anemia studies, no side effects or adverse
events were observed in the current study.
Improved noninvasive lymph node staging in cancer is
critical to improving therapeutic outcomes by better selection
of appropriate therapies for patients. In prostate cancer, for
example, nodal involvement has been decreasing steadily
because the advent of prostate-specific antigen (PSA) screen-
ing and earlier stage presentation. However, there has also
been a trend toward more limited lymph node dissections,
eliminating the external iliac dissection [21]. These smaller
procedures may leave more patients with cancer in place
postprostatectomy. More accurate preoperative nodal imaging
will help select patients for larger lymph node dissections.
Moreover, it may even eliminate the need for surgery at all,
as the identification of malignant lymph nodes before radical
prostatectomy often results in abandonment of a surgical ap-
proach in favor of castration therapy, potentially with radiation.
Magnetic nanoparticles have significant promise to im-
prove lymph node staging. Our data indicate that ferumoxytol,
a third-generation MNP, has potential as a lymph node stag-
ing agent with improved safety profiles and easier delivery.
Moreover, we anticipate that this material may also have
the potential to better delineate primary tumors, to map the
vascular supply of primary tumors preoperatively, to image
angiogenic changes associated with therapies, and to de-
tect metastases to other organs. An approval for its anemia
indication along with the feasibility data from this study will
allow for our planned larger studies to evaluate incremental
dosing, sensitivity, specificity, and ultimately the clinical value
of this nanomaterial for cancer patients.
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